Top View
- Pathophysiology of Dyskinesia and Behavioral Disorders in Non-Human Primates: Insights from Multimodal Imaging
- Neuroprotection Or Neurotoxicity of Illicit Drugs on Parkinson's Disease
- High-Resolution Respirometry Reveals MPP+ Mitochondrial Toxicity Mechanism in a Cellular Model of Parkinson’S Disease
- Dopamine Transporter Expression Confers Cytotoxicity to Low Doses of the Parkinsonism-Inducing Neurotoxin 1 -Methyl=4=Phenylpyridinium
- Mitochondrial Complex I Inhibition Is Not Required for Dopaminergic Neuron Death Induced by Rotenone, MPP؉, Or Paraquat
- Neuroprotective Effect of Optimized Yinxieling Formula in 6-OHDA-Induced Chronic Model of Parkinson's Disease Through the Inflammation Pathway
- Understanding Clandestine Synthetic Drugs
- 1349 Illicit Drugs, Legal Highs and Over-Consumption Of
- Dopaminergic Neurons Regenerate Following Chemogenetic Ablation in the Olfactory Bulb of Adult Zebrafish (Danio Rerio)
- Enantiomersin Vitroand in the MPTP-Lesioned Primate:R-MDMA
- Free PDF Download
- Effect of Ginsenoside Rb1 on Lipid Peroxidation and Neurotoxicity Induced by MPTP in Liver and Brain of Mouse
- How Do Drugs and Hormones Influence Behavior?
- Download Product Insert (PDF)
- Imaging of Dopamine Transporter in Rodents Using PET and SPECT
- Effect of Adenosine a Receptor Antagonists on Motor Disorders Induced by 6-Hydroxydopamine in Rat1
- Ginsenoside Re Protects Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice Via Upregulation of Dynorphin-Mediated Κ-Opi
- NIOSH Method 9106: Methamphetamine and Illicit Drugs, Precursors, and Adulterants on Wipes by Liquid-Liquid Extraction
- Genetic Or Toxicant Induced Disruption of Vesicular Monoamine Storage and 2 Global Metabolic Profiling in Caenorhabditis Elegans
- Neuron-Astrocyte Interactions in Parkinson's Disease
- Characterization of Motor, Depressive-Like and Neurochemical
- MPTP and Monoamine Oxidase B Inhibitors
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- Parkinsonism-Inducing Neurotoxin, N-Methyl-4-Phenyl-1,2,3,6
- Original Article Distribution Characteristics of Vesicular Monoamine Transporter in Brain of Mice with Parkinson Disease
- Prostaglandin E2 in Oxidopamine-Induced Neuronal Inflammation and Injury
- Mptp and Drug-Induced Parkinson's
- Drugs and the Brain: an Introduction to Neuropharolacology
- RCRA Hazardous Waste Identification of Methamphetamine Production Process By-Products
- UWA-121, a Mixed Dopamine and Serotonin Re-Uptake Inhibitor, Enhances L-DOPA Anti-Parkinsonian Action Without Worsening Dyskines
- Models of Parkinson's Disease
- Effect of Temperature on Dopamine Transporter Function and Intracellular Accumulation of Methamphetamine
- Cyclooxygenase-2 Contributes to Oxidopamine-Mediated Neuronal Inflammation and Injury Via the Prostaglandin E2 Receptor EP2 Subt
- The Mitochondrial Permeability Transition: Nexus of Aging, Disease and Longevity
- Activation MPTP Neurotoxicity by Inhibiting Microglial Nigrostriatal Dopaminergic Neurons Against Cannabinoid Receptor Type 1 Pr
- The Organic Cation Transporter-3 Is a Pivotal Modulator of Neurodegeneration in the Nigrostriatal Dopaminergic Pathway
- Drugs of Abuse (2017 Edition)
- Increased Vesicular Monoamine Transporter Enhances Dopamine Release and Opposes Parkinson Disease-Related Neurodegeneration in Vivo
- Increased Vulnerability of Nigrostriatal Terminals in DJ-1-Deficient Mice Is Mediated by the Dopamine Transporter ⁎ Amy B